The Assam Tribune

Phase 1 data shows Covaxin safe: Lancet


NEW DELHI, Jan 22: Covaxin, India!s first indigenous vaccine against COVID-19, showed enhanced immune response without any serious side effects in the participan­ts enrolled for the phase 1 trials, according to the results published in The Lancet Infectious Disease journal.

Developed by Bharat Biotech in collaborat­ion with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), Pune, the vaccine has been granted emergency use authorisat­ion in clinical trial mode! by the Indian government.

Covaxin, which is now undergoing phase 3 trials, had raised concerns among experts over its emergency approval earlier this month by India's drug regulator.

The vaccine, codenamed BBV152, was well tolerated in all dose groups with no vaccinerel­ated serious adverse events, noted the authors of the study funded by Bharat Biotech. The same results were earlier published in the preprint server medRxiv in December. However, there has been no new data released in the public domain which could demonstrat­e further safety and efficacy of the preventive.

The authors said that all adverse events were mild and moderate, and were more frequent after the first dose, adding that one adverse event was reported but was unrelated to the vaccine.

The randomised phase 1 trial to assess the safety and immunogeni­city of BBV152 was carried at 11 hospitals across India. Adults aged 18-55 years who were deemed healthy by the investigat­or were eligible. Between July 13 and 30, last year, 827 participan­ts were screened, of whom 375 were enrolled. Among the enrolled participan­ts, 100 each were randomly assigned to the three vaccine groups, and 75 were randomly assigned to the control group. Two intramuscu­lar doses of vaccines were administer­ed 14 days apart.

Newspapers in English

Newspapers from India